Literature DB >> 12499237

Use of macrolides for Q fever.

Didier Raoult.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12499237      PMCID： PMC149039          DOI： 10.1128/AAC.47.1.446.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  4 in total

1.  Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii.

Authors:  D Raoult; H Torres; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

2.  In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis.

Authors:  J M Rolain; M Maurin; A Bryskier; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Newer macrolides as empiric treatment for acute Q fever infection.

Authors:  A Gikas; D P Kofteridis; A Manios; J Pediaditis; Y Tselentis
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

4.  In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin.

Authors:  A Gikas; I Spyridaki; A Psaroulaki; D Kofterithis; Y Tselentis
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191
  4 in total
  1 in total

1.  Azithromycin for acute Q fever in pregnancy.

Authors:  Dasa Cerar; Primoz Karner; Tatjana Avsic-Zupanc; Franc Strle
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.